• Mary-Katharine Collins, Jacqueline F Moreau, Dan Opel, James Swan, Noel Prevost, Matthew Hastings, Eleanor Bimla Schwarz, and Laura Korb Ferris.
• School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
• J. Am. Acad. Dermatol. 2014 Jan 1;70(1):55-9.

BackgroundApproximately 150 women annually become pregnant while taking isotretinoin despite participation in the iPLEDGE program. Noncompliance with the requirement to be abstinent or use 2 contraceptive methods may be a contributing factor.ObjectiveWe sought to determine the degree of adherence to contraception or abstinence among women taking isotretinoin.MethodsWe conducted an anonymous survey of women of childbearing potential taking isotretinoin for at least 2 months.ResultsAmong 75 participants, 21 (28%) chose abstinence as their primary means of pregnancy prevention, of whom 4 (19%) were sexually active during treatment. The most commonly chosen contraceptive methods among the 39 women who were sexually active were condoms (35, 90%) and oral contraceptive pills (18, 46%). Twelve women (31%) admitted to having intercourse at least once using 1 or fewer forms of contraception; 10 failed to use condoms, and 1 reported completely unprotected intercourse. Among sexually active oral contraceptive pill users, 7 (39%) reported missing 1 or more pills in the previous month.LimitationsData were self-reported, thus participants may have inaccurately reported contraception use.ConclusionsEncouraging the use of highly effective, patient-independent contraception and limiting abstinence to women who have never been sexually active may further reduce the rate of isotretinoin-exposed pregnancies.Copyright © 2013 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

26 keywords...

hide…